

CATALYST PHARMACEUTICALS, INC.

FORM RW (Withdrawal of Registration Statement)

Filed 12/23/16

Address	355 ALHAMBRA CIRCLE SUITE 1250 CORAL GABLES, FL 33134
Telephone	(305) 529-2522
CIK	0001369568
Symbol	CPRX
SIC Code	2834 - Pharmaceutical Preparations
Industry	Biotechnology & Medical Research
Sector	Healthcare
Fiscal Year	12/31

Catalyst Pharmaceuticals, Inc.
355 Alhambra Circle
Suite 1250
Coral Gables, Florida 33134

United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, NE
Washington, DC 20549
Attention: Suzanne Hayes
Assistant Director
Office of Insurance and Healthcare

VIA EDGAR AND OVERNIGHT COURIER

Ladies and Gentlemen:

On behalf of Catalyst Pharmaceuticals, Inc., a Delaware corporation (the “Company”), we hereby request, pursuant to Section 477 of the Securities Act of 1933, as amended (the “Securities Act”), that Post-Effective Amendment No. 1 to the Company’s Registration Statement on Form S-3, Registration No. 333-193699, filed with the Securities and Exchange Commission (“SEC”) on December 6, 2016 (the “Post-Effective Amendment”) be withdrawn effective immediately. The Post-Effective Amendment is being withdrawn at the request of the SEC and will be replaced by the filing of a new registration statement. The Post-Effective Amendment has not been declared effective and none of the Company’s securities has been sold pursuant to the Post-Effective Amendment.

Accordingly, we request that the SEC issue an order granting the withdrawal of the Post-Effective Amendment (“Order”) effective as of the date hereof or at the earliest practicable date hereafter. Please provide a copy of the Order to Philip B. Schwartz, Esq. of Akerman LLP, via email at philip.schwartz@akerman.com or via facsimile at (305) 349-4833.

This withdrawal affects only the Post-Effective Amendment and does not otherwise affect the Company’s Registration Statement on Form S-3, Registration No. 333-193699.

Should you have any questions regarding this request for withdrawal, please contact Philip B. Schwartz at (954) 468-2455.

Very Truly Yours,

/s/ Alicia Grande

Alicia Grande
Chief Financial Officer
Catalyst Pharmaceuticals, Inc.

cc: Philip B. Schwartz, Akerman LLP
Dorrie Yale, Securities and Exchange Commission
Mary Beth Breslin, Securities and Exchange Commission